NEW YORK, NY / ACCESSWIRE / June 28, 2022 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

First High-School Education Group Co., Ltd. (NYSE:FHS)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/first-high-school-education-group-co-ltd-loss-submission-form?prid=29307&wire=1
Lead Plaintiff Deadline: July 11, 2022
This lawsuit is on behalf of all persons or entities who purchased FHS American Depositary Shares in or traceable to the Company’s March 2021 initial public offering.

Allegations against FHS include that: (a) the new rules, regulations and policies to be implemented by the Chinese government following the Two Sessions parliamentary meetings were far more severe than represented to investors and posed a material adverse threat to the Company and its business; (b) contemplated Chinese regulations and rules regarding private education were leading to a slowdown of government approval to open new educational facilities which would have a negative effect on FHS’s enrollment and growth; and (c) as a result, representations made in connection with the Company’s initial public offering regarding FHS’s historical financial and operational metrics and purported market opportunities did not accurately reflect the actual business, operations, and financial results and trajectory of the Company at the time of the initial public offering, and were materially false and misleading and lacked a factual basis.

Oscar Health, Inc. (NYSE:OSCR)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/oscar-health-inc-loss-submission-form?prid=29307&wire=1
Lead Plaintiff Deadline: July 11, 2022
This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Oscar Class A common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company’s March 2021 initial public offering.

Allegations against OSCR include that: (1) Oscar was experiencing growing COVID-19 testing and treatment costs; (2) Oscar was experiencing growing net COVID costs; (3) Oscar would be negatively impacted by an unfavorable prior year Risk Adjustment Data Validation result relating to 2019 and 2020; (4) Oscar was on track to be negatively impacted by significant SEP membership growth; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Axsome Therapeutics, Inc. (NASDAQ:AXSM)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/axsome-therapeutics-inc-loss-submission-form?prid=29307&wire=1
Lead Plaintiff Deadline: July 12, 2022
Class Period: December 30, 2019 – April 22, 2022

Allegations against AXSM include that: (i) Axsome’s chemistry, manufacturing, and control (“CMC”) practices were deficient with respect to AXS-07, the Company’s medicine for the acute treatment of migraine, and its manufacturing process; (ii) as a result, Axsome was unlikely to submit the AXS-07 New Drug Application (“NDA”) on its initially represented timeline; (iii) the foregoing CMC issues remained unresolved at the time that the U.S. Food and Drug Administration (“FDA”) reviewed the AXS-07 NDA; (iv) accordingly, the FDA was unlikely to approve the AXS-07 NDA; (v) as a result of all the foregoing, Axsome had overstated AXS-07’s regulatory and commercial prospects; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.

To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]

SOURCE: The Law Offices of Vincent Wong

View source version on accesswire.com:
https://www.accesswire.com/706808/SHAREHOLDER-ALERT-FHS-OSCR-AXSM-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines